The purpose of this study is to determine the efficacy and cost-effectiveness of long-term pharmacotherapy (using Zyban and/or nicotine replacement) for reducing the relapse rate associated with stopping smoking.

Condition	Treatment or Intervention
Tobacco Use Disorder	Drug: Bupropion

Ages Eligible for Study:  21 Years   -   75 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Patients who smoke at least 10 cigarettes daily and have attempted to quit smoking at least once

Exclusion Criteria:

• Seizure History
• Unstable Blood Pressure
• Current major depression
• Current alcohol/drug abuse or dependency
• Lifetime psychotic illness
• Current use of psychotropic drugs
• Unstable medical condition

Lirio S. S Covey, Ph.D.      (212)543-5736    lsc3@columbia.edu

New York
      New York State Psychiatric Institute, New York,  New York,  10032,  United States; Recruiting

Study chairs or principal investigators

Lirio S. S Covey, Ph.D.,  Principal Investigator,  Research Foundation for Mental Hygiene, Inc.   

Study ID Numbers:  NIDA-13490-1; R01-13490-1
Record last reviewed:  June 2003
Record first received:  June 25, 2003
ClinicalTrials.gov Identifier:  NCT00063323
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08